GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NxStage Medical Inc (NAS:NXTM) » Definitions » EV-to-EBITDA

NxStage Medical (NxStage Medical) EV-to-EBITDA : 63.97 (As of Apr. 25, 2024)


View and export this data going back to 2005. Start your Free Trial

What is NxStage Medical EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NxStage Medical's enterprise value is $2,000.5 Mil. NxStage Medical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2018 was $31.3 Mil. Therefore, NxStage Medical's EV-to-EBITDA for today is 63.97.

The historical rank and industry rank for NxStage Medical's EV-to-EBITDA or its related term are showing as below:

NXTM's EV-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 15.23
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), NxStage Medical's stock price is $30.00. NxStage Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.080. Therefore, NxStage Medical's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


NxStage Medical EV-to-EBITDA Historical Data

The historical data trend for NxStage Medical's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NxStage Medical EV-to-EBITDA Chart

NxStage Medical Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.72 194.89 80.98 58.08 77.81

NxStage Medical Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.90 77.81 78.74 82.98 57.10

Competitive Comparison of NxStage Medical's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, NxStage Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NxStage Medical's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NxStage Medical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NxStage Medical's EV-to-EBITDA falls into.



NxStage Medical EV-to-EBITDA Calculation

NxStage Medical's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2000.540/31.275
=63.97

NxStage Medical's current Enterprise Value is $2,000.5 Mil.
NxStage Medical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NxStage Medical  (NAS:NXTM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

NxStage Medical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=30.00/-0.080
=At Loss

NxStage Medical's share price for today is $30.00.
NxStage Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.080.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


NxStage Medical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NxStage Medical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


NxStage Medical (NxStage Medical) Business Description

Traded in Other Exchanges
N/A
Address
NxStage Medical develops and manufactures products and services for patients with chronic or acute kidney failure. The firm operates in three segments: System One, In-Center, and Services. The System One segment contributes the majority of revenue. It sells and rents the System One portable hemodialysis systems and related consumable products for home and critical care hemodialysis treatments. The In-Center segment sells blood tubing sets and needles for hemodialysis, primarily to dialysis clinics. This business has a high degree of customer concentration. The Services business provides dialysis to customers at NxStage Kidney Care dialysis centers. NxStage generates the majority of its revenue in the United States.
Executives
Earl R Lewis director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Craig W Moore director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Jeffrey H Burbank director, officer: Chief Executive Officer NXSTAGE MEDICAL INC, 439 SOUTH UNION STREET 5TH FLOOR, LAWRENCE MA 01843
James J Peters director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Heyward R Donigan director 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451
Jean K Mixer director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Kevin Hershberger officer: Chief Accounting Officer 350 MERRIMACK STREET, LAWRENCE MA 01843
Philippe O. Chambon director C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

NxStage Medical (NxStage Medical) Headlines

From GuruFocus

B. Braun to Acquire Bloodlines Business of NxStage Medical, Inc.

By Marketwired Marketwired 07-19-2018

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,000 Shares

By GuruFocus Research GuruFocus Editor 06-17-2010

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares

By GuruFocus Research GuruFocus Editor 12-17-2010

NxStage Celebrates Fifth Annual National Home Hemodialysis Day

By PRNewswire PRNewswire 03-15-2018

Medisystems Announces US Release of MasterGuard® Plus

By PRNewswire PRNewswire 04-13-2018